Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)

Author(s): Simone Fulda

Journal Name: Current Signal Transduction Therapy

Volume 3 , Issue 3 , 2008

Become EABM
Become Reviewer
Call for Editor


Since cell death by apoptosis is critical for the maintenance of tissue homeostasis, dysregulation of the cells intrinsic death program may promote tumor formation and progression. In addition, most anticancer therapies used in clinical oncology primarily act by triggering apoptosis in cancer cells. Therefore, defects in apoptosis programs, for example aberrant expression of antiapoptotic proteins, may render cancer cells resistant to current treatment approaches. “Inhibitor of Apoptosis Proteins” (IAPs) are expressed at high level in many human cancers and block apoptosis at a central point by binding to and inhibiting effector caspases. Thus, strategies that target IAPs, e.g. antisense approaches or small molecule inhibitors, open new perspectives to either directly trigger apoptosis in cancer cells or to restore sensitivity for apoptosis induction by cytotoxic therapies.

Keywords: ”Inhibitor of Apoptosis Proteins“ (IAPs), homeostasis, anticancer therapies, oncology, cancer cells, antiapoptotic proteins, NMR - Screening, XIAP antagonists

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [168 - 173]
Pages: 6
DOI: 10.2174/157436208785699686
Price: $65

Article Metrics

PDF: 1